Welcome to our dedicated page for Abbvie news (Ticker: ABBV), a resource for investors and traders seeking the latest updates and insights on Abbvie stock.
AbbVie Inc. reports pharmaceutical developments across immunology, neuroscience, oncology and Allergan Aesthetics. Recurring updates include financial results by product portfolio, clinical and real-world data for therapies such as SKYRIZI and RINVOQ, FDA regulatory submissions and response letters, and medical-conference presentations in inflammatory bowel disease and other immune-mediated conditions.
Company news also covers pipeline spending, acquired in-process research and development, manufacturing capacity for medicines in core therapeutic areas, and investor conference appearances. AbbVie’s product references commonly include SKYRIZI, RINVOQ, Botox Therapeutic, Vraylar, Ubrelvy, Qulipta, Venclexta, Imbruvica and Elahere.
AbbVie (NYSE: ABBV) reported topline Phase 3 EPCORE DLBCL-1 results for epcoritamab in relapsed/refractory diffuse large B-cell lymphoma (DLBCL) on Jan 16, 2026. The trial enrolled 483 patients (73% with ≥2 prior lines) and showed improved progression-free survival (PFS) with HR 0.74 (95% CI 0.60–0.92). Improvements were also seen in complete response rate, duration of response, and time to next treatment. The study did not show a statistically significant overall survival benefit (OS HR 0.96; 95% CI 0.77–1.20). Safety was described as consistent with known epcoritamab profile. AbbVie and Genmab plan regulatory discussions and future data presentation.
AbbVie (NYSE: ABBV) announced a voluntary three-year agreement with the Trump administration on January 12, 2026 to expand access and affordability while protecting U.S. pharmaceutical investment. AbbVie will provide low prices in Medicaid, expand direct-to-patient offerings through TrumpRx for medicines used by millions (including ALPHAGAN, COMBIGAN, HUMIRA and SYNTHROID), and commit $100 billion in U.S. research, development and capital investments, including manufacturing, over the next decade. The agreement includes an exemption from tariffs and future pricing mandates; further terms remain confidential.
AbbVie (NYSE: ABBV) and RemeGen announced an exclusive licensing agreement dated Jan. 12, 2026 for RC148, a PD-1/VEGF bispecific antibody in development for multiple advanced solid tumors including NSCLC and colorectal cancer.
Under the deal, AbbVie gains exclusive rights to develop, manufacture, and commercialize RC148 outside the Greater China territory. RemeGen received a $650 million upfront payment and is eligible for up to $4.95 billion in development, regulatory, and commercial milestones, plus tiered double-digit royalties on net sales outside Greater China. Early clinical studies reported initial favorable antitumor activity for RC148 in combination with an ADC; AbbVie intends to explore combinations with its ADC programs including telisotuzumab adizutecan (Temab-A).
AbbVie (NYSE:ABBV) agreed to acquire a device manufacturing facility and associated intellectual property from West Pharmaceutical Services (NYSE:WST) in Tempe, Arizona, expanding its drug delivery device manufacturing capacity.
AbbVie plans to hire approximately 200 employees at the site and to invest more than $175 million to acquire, modernize, and integrate the facility into its global network. The deal transfers multiple production lines and 3.5 mL on-body injector technology to support current and next-generation immunology and neuroscience medicines. The transaction is anticipated to close in mid-2026, subject to closing conditions, and is part of AbbVie's broader plan to invest >$10 billion in U.S. capital over the next decade.
West (NYSE: WST) agreed to sell all manufacturing and supply rights for the SmartDose 3.5mL On-Body Delivery System and associated facilities to AbbVie (NYSE: ABBV) for $112.5 million at close, subject to working capital and other adjustments.
The definitive agreement is subject to closing conditions and is expected to close in mid-2026. West will continue commercial supply and execute ongoing project commitments prior to close, which may include milestone-based payments before closing.
SmartDose 3.5mL revenues represented approximately 4% of fiscal 2025 revenue. West said it will provide more details when it issues 2026 guidance on its Q4 2025 earnings call in February. The company will continue development and manufacture of other SmartDose products, including the SmartDose 10mL system.
AbbVie (NYSE: ABBV) will report full-year and fourth-quarter 2025 financial results on Wednesday, February 4, 2026, before the market opens. The company will host a live webcast of the earnings conference call at 8:00 a.m. Central time accessible via its investor relations site at investors.abbvie.com. An archived edition of the session will be available later that day.
AbbVie (NYSE: ABBV) will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026. Management will participate in a fireside chat at 10:15 a.m. Central time.
A live audio webcast will be accessible via AbbVie’s Investor Relations website at investors.abbvie.com, and an archived edition of the session will be available later the same day.
AbbVie (NYSE: ABBV) will present new ASH 2025 data across multiple blood cancers, including MM, FL, CLL, DLBCL, AML and AL. Key trial highlights include EPCORE FL-1 phase 3 results showing PFS HR 0.21 (79% risk reduction) and ORR 95.7% for epcoritamab+R2 vs 81.0% with R2; CLL17 fixed-duration venetoclax arms meeting non-inferiority versus ibrutinib with ~3-year PFS ≈81%; etentamig (ABBV-383) combination ORR 81% in heavily pretreated MM; and PVEK+VEN+AZA CR rate 63.3% in newly diagnosed AML unfit for intensive chemo.
Safety signals include higher grade 3/4 neutropenia and infections across several regimens; investigational agents remain under study.
AbbVie (NYSE: ABBV) will present at the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3, 2025. Management will take part in a fireside chat at 7:30 a.m. Central time. A live audio webcast will be available via AbbVie's investor relations site, and an archived recording will be posted later the same day.
AbbVie (NYSE: ABBV) announced U.S. FDA approval of EPKINLY (epcoritamab-bysp) in combination with rituximab and lenalidomide (EPKINLY + R2) for adult patients with relapsed or refractory follicular lymphoma after ≥1 prior systemic therapy.
The approval follows Phase 3 EPCORE FL-1 where EPKINLY + R2 reduced risk of progression or death by 79% (HR 0.21), achieved 89% ORR and 74% complete response, and median PFS was not reached versus 11.2 months for R2. Safety was consistent with known profiles; CRS occurred in 24% (mostly Grade 1–2).